Vertex Pharmaceuticals (VRTX) Assets Average (2010 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Assets Average of $26.1 billion for Q1 2026, up 14.78% year-over-year from $22.7 billion in Q1 2025, and up 3.21% quarter-over-quarter from $25.3 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Assets Average (2010 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $26.1 billion for Q1 2026.
- In Q1 2026, Assets Average rose 14.78% year-over-year to $26.1 billion; the TTM figure through Mar 2026 stood at $26.1 billion (up 14.78% YoY), while the FY2025 annual figure was $24.1 billion, up 6.44% from the prior year.
- Assets Average for Q1 2026 stood at $26.1 billion, up from $25.3 billion in the prior quarter.
- The five-year high for Assets Average was $26.1 billion in Q1 2026, with the low at $13.8 billion in Q1 2022.
- The 5-year median for Assets Average is $22.0 billion (2024), against an average of $20.9 billion.
- The sharpest annual moves came in 2023 and 2025: Assets Average surged 34.08% in 2023, then dropped 2.65% in 2025.
- Vertex Pharmaceuticals' Assets Average stood at $17.4 billion in 2022, then rose by 27.54% to $22.2 billion in 2023, then grew by 0.71% to $22.4 billion in 2024, then gained by 12.8% to $25.3 billion in 2025, then climbed by 3.21% to $26.1 billion in 2026.
- Business Quant data shows VRTX's Assets Average at $26.1 billion in Q1 2026, $25.3 billion in Q4 2025, and $24.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.95 Bn |
| Mar 31, 2026 | 26.06 Bn |
| Dec 31, 2025 | 25.25 Bn |
| Sep 30, 2025 | 24.45 Bn |
| Jun 30, 2025 | 23.46 Bn |
| Mar 31, 2025 | 22.71 Bn |
| Dec 31, 2024 | 22.39 Bn |
| Sep 30, 2024 | 21.19 Bn |
| Jun 30, 2024 | 22.02 Bn |
| Mar 31, 2024 | 23.32 Bn |
| Dec 31, 2023 | 22.23 Bn |
| Sep 30, 2023 | 21.04 Bn |
| Jun 30, 2023 | 19.66 Bn |
| Mar 31, 2023 | 18.56 Bn |
| Dec 31, 2022 | 17.43 Bn |
| Sep 30, 2022 | 16.14 Bn |
| Jun 30, 2022 | 14.92 Bn |
| Mar 31, 2022 | 13.84 Bn |
| Dec 31, 2021 | 13.03 Bn |
| Sep 30, 2021 | 12.42 Bn |